| John T Yoo, | |
|
72 Netherwood Cir, Edison, NJ 08820-1659 | |
| (551) 574-2896 | |
| Not Available |
| Full Name | John T Yoo |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 4 Years |
| Location | 72 Netherwood Cir, Edison, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871105338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 131382 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trustees Of Columbia University In The City Of New York | 8527972546 | 1895 |
News Archive
FEI (NASDAQ: FEIC) announces the sale of a complete correlative workflow to the University of Maastricht. The systems will be installed at the University's Institute of Nanoscopy, a new research facility that will use the high-resolution microscopes to understand the working mechanisms of protein complexes in an effort to develop new and improved treatment and prevention for disease, such as cancer and tuberculosis.
Biomoda, Inc., a development stage medical diagnostics company, announced it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its invention directed to the "Method for Prognosing Response to Cancer Therapy with 5,10,15,20-Tetrakis (Carboxyphenyl) Porphine."
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A study led by Efrem S. Lim of Arizona State University confirms evidence of the B.1.243.1 with an E484K mutation on the spike protein.
› Verified 3 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
FEI (NASDAQ: FEIC) announces the sale of a complete correlative workflow to the University of Maastricht. The systems will be installed at the University's Institute of Nanoscopy, a new research facility that will use the high-resolution microscopes to understand the working mechanisms of protein complexes in an effort to develop new and improved treatment and prevention for disease, such as cancer and tuberculosis.
Biomoda, Inc., a development stage medical diagnostics company, announced it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its invention directed to the "Method for Prognosing Response to Cancer Therapy with 5,10,15,20-Tetrakis (Carboxyphenyl) Porphine."
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A study led by Efrem S. Lim of Arizona State University confirms evidence of the B.1.243.1 with an E484K mutation on the spike protein.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John T Yoo, 72 Netherwood Cir, Edison, NJ 08820-1659 Ph: (551) 574-2896 | John T Yoo, 72 Netherwood Cir, Edison, NJ 08820-1659 Ph: (551) 574-2896 |
News Archive
FEI (NASDAQ: FEIC) announces the sale of a complete correlative workflow to the University of Maastricht. The systems will be installed at the University's Institute of Nanoscopy, a new research facility that will use the high-resolution microscopes to understand the working mechanisms of protein complexes in an effort to develop new and improved treatment and prevention for disease, such as cancer and tuberculosis.
Biomoda, Inc., a development stage medical diagnostics company, announced it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its invention directed to the "Method for Prognosing Response to Cancer Therapy with 5,10,15,20-Tetrakis (Carboxyphenyl) Porphine."
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A study led by Efrem S. Lim of Arizona State University confirms evidence of the B.1.243.1 with an E484K mutation on the spike protein.
› Verified 3 days ago
Andres Felipe Sepulveda, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 65 James St, Edison, NJ 08820 Phone: 732-321-7000 |